T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

SAN FRANCISCO, March 31, 2025 /PRNewswire/ -- The Parker Institute for Cancer Immunotherapy (PICI) today announced the appointment of Karen E. Knudsen, MBA PhD as its new chief executive officer. A ...

When she first got her cancer diagnosis years ago, 84-year-old Dukhi Hong couldn’t have imagined coming this far. “It feels ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

A discovery published in Nature Immunology has shed light on why the immune system is less aggressive toward self-antigens, ...

Melanoma cells, the most aggressive form of skin cancer, produce a protein that blocks the recognition and removal of the ...

Joshua Rabinowitz will direct Princeton’s role in the Weill Cancer Hub East, a collaboration with The Rockefeller University, ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...